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ABSTRACT
Dysregulation of alternative splicing (AS) is one of the molecular hallmarks 
of cancer, with splicing alteration of numerous genes in cancer patients. However, 
studying splicing mis-regulation in cancer is complicated by the large noise generated 
from tissue-specific splicing. To obtain a global picture of cancer-specific splicing, we 
analyzed transcriptome sequencing data from 1149 patients in The Cancer Genome Atlas 
project, producing a core set of AS events significantly altered across multiple cancer 
types. These cancer-specific AS events are highly conserved, are more likely to maintain 
protein reading frame, and mainly function in cell cycle, cell adhesion/migration, and 
insulin signaling pathways. Furthermore, these events can serve as new molecular 
biomarkers to distinguish cancer from normal tissues, to separate cancer subtypes, and 
to predict patient survival. We also found that most genes whose expression is closely 
associated with cancer-specific splicing are key regulators of the cell cycle. This study 
uncovers a common set of cancer-specific AS events altered across multiple cancers, 
providing mechanistic insight into how splicing is mis-regulated in cancers.
INTRODUCTION
Most human genes undergo alternative splicing (AS) 
to produce multiple isoforms with different biological 
properties. This process is tightly controlled across different 
tissues and developmental stages, and dysregulation of 
AS is closely associated with various human diseases 
including cancer [1, 2]. The extensive alteration of AS is 
considered to be one of the molecular hallmarks of cancer 
[3], and affects numerous genes that are critical for tumor 
pathogenesis and progression (e.g. apoptosis, angiogenesis, 
tumor metastasis) [4]. While most genetic mutations occur 
at a low frequency in cancer patients (with a few exceptions 
like TP53), many identified cancer-specific AS events were 
found in more than half of the tumor samples, suggesting 
a predominant role of splicing dysregulation in cancer [1, 
4]. For example, CD44 is a key mediator of cell-cell and 
cell-matrix interactions, migration and invasion [5], and 
different splicing isoforms of CD44 have been linked with 
tumor evasion and metastasis in many cancers [6–8]. Other 
well-documented cases include the apoptosis regulator 
Bcl-x, which can shift its splicing from pro-apoptotic into 
anti-apoptotic isoforms in cancers [9].
AS is generally regulated by multiple cis-acting 
splicing regulatory elements (SREs) that are specifically 
bound by trans-acting splicing factors to enhance or inhibit 
the use of nearby splice sites [10, 11]. The same splicing 
factor may either activate or inhibit splicing by binding to 
its cognate SREs in different pre-mRNA regions, which is 
commonly referred to as context dependent activity [12–
14]. Various cellular signaling pathways, such as the MEK/
ERK or c-Myc pathway [15–17], were found to control 
the expression level and activity of splicing factors, which 
in turn determine different splicing patterns in distinct 
tissues (reviewed in [10, 18]). Many splicing factors are 
involved in cancer pathogenesis through mediating AS of 
hundreds of genes [4]. For example, the splicing factor 
SRSF1 is found to act as a proto-oncogene to promote 
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cell transformation [19], whereas the splicing suppressor 
RBM4 functions as a tumor suppressor to inhibit tumor 
progression [20]. These two antagonistic factors control a 
partially overlapping set of AS events that are involved in 
cell migration and apoptosis [20].
While the global change of splicing in cancers 
is being increasingly appreciated, the functional 
consequences and regulatory mechanisms of cancer-
specific AS remain poorly understood. In addition, detailed 
analyses of cancer-associated splicing were previously 
focused on single tumor types or specific genes [21, 22], 
which is often dominated by the noise from tissue specific 
AS events. Since cancer is a highly heterogeneous disease, 
the genetic variation between samples has made the 
identification of cancer-specific splicing isoforms difficult. 
Recent advance in The Cancer Genome Atlas (TCGA) 
project has provided tremendous amounts of sequencing 
data from the transcriptome of thousands of samples in 
different cancer types [23], making it possible for an 
unbiased identification and a further analysis of “cancer-
specific” splicing events across different cancer types.
In this study, we performed a transcriptome-wide 
splicing comparison between thousands of tumor samples 
and paired normal controls to identify a large number 
of splicing events with altered splicing in cancer. Most 
of these events were found to change in a single cancer 
type, and we further identified a core set of cancer-specific 
AS events across three different cancer types. The genes 
containing cancer-specific AS events are significantly 
enriched for functions in cell cycle, cell adhesion/
migration, and insulin signaling pathway. Detailed analyses 
suggested that cancer-specific cassette exons are more 
conserved among vertebrates and more likely to maintain 
the protein reading frame. The set of cancer-specific AS 
events can serve as reliable biomarkers to separate tumor 
from normal samples and to even distinguish different 
subtypes of breast cancer. Finally, we found that most 
genes whose expression is closely associated with cancer-
specific splicing are also key regulators of cell cycle, 
providing a previously unknown link between cell cycle 
and splicing regulation in cancer cells.
RESULTS
Identification of cancer-specific AS events 
common to multiple cancers
It is well known that splicing is controlled in a 
tissue specific manner with a global change of the splicing 
landscape between different tissues [24, 25]. Thus 
identification of AS events altered in cancer vs. normal 
cells is often complicated by the tissue types used. It 
remains unclear what portion of AS events are commonly 
mis-regulated across all cancer types vs. those specific 
to certain cancers. To identify cancer-specific AS events 
that are changed within and/or across multiple cancers, 
we used RNA-seq data collected through TCGA project 
[23]. The aligned RNA-seq reads were processed through 
the MISO pipeline to estimate ratios of different splicing 
isoforms for each annotated splicing event. For each AS 
event, we calculated the PSI (Percent Spliced In) values 
between all normal and tumor samples, and identified 
potential cancer-specific AS events that are significantly 
altered in cancer vs. normal tissues (Figure 1A).
For a reliable comparison, we selected three types 
of cancers that have sufficient number of paired normal 
samples from TCGA, including breast invasive carcinoma 
(BRCA), lung squamous cell carcinoma (LUSC) and 
liver hepatocellular carcinoma (LIHC). We focused 
on four major modes of AS for more detailed analysis: 
skipped exon (SE), retained intron (RI), alternative 3’ 
splice site (A3SS) and alternative 5’ splice site (A5SS). 
In each cancer type, we identified AS events that satisfy 
the following criteria: (i) the AS event is detected in at 
least 10 tumor samples and 10 normal samples; (ii) the 
distributions of PSI values of each event are significantly 
different between normal and tumor samples (p < 0.05 by 
t-test); (iii) the mean difference of PSI values between 
normal and tumor samples is large than 0.1 (Figure 1B). 
For each cancer type, we identified several thousand 
AS events that have significant changes of the splicing 
isoforms (Table 1). Most of these events are specific to a 
single cancer type, with lung cancer having more altered 
AS events compare to breast and liver cancers, probably 
due to the higher mutation rate in lung cancer [26].
We considered the common events that changed 
in all three types of cancers as a core set of 163 cancer-
specific AS events (Figure 1B and Supplementary Table 
S1). As a background control, we simulated the overlaps 
of AS events between different cancer types using 1000 
randomly selected datasets with matched size (see 
methods). In all four AS modes, the overlaps between 
simulated datasets are significantly smaller than those 
between real set, especially for the overlaps of all three 
cancers (Figure 1C). This result suggests that although each 
cancer type has tissue-specific set of splicing events, there 
are indeed a significant number of splicing events shared 
by multiple cancers. Strikingly, 10 of the genes that show 
cancer-specific AS are also frequently mutated in cancers 
vs. normal samples [27]. Such overlap is significantly 
more than the overlap expected by chance (p = 10-6 by 
hypergeometric test), indicating that the function of these 
genes may be altered through either mutation or splicing 
changes to affect cancer progression. This result also 
suggests that, in addition to point mutations and copy 
number variations, the alteration of splicing may serve as 
another important route to alter gene function in cancer.
Splicing of most introns is regulated in a 
co-transcriptional fashion [18], thus a change in gene 
expression may affect AS outcomes of corresponding 
genes. We examined the genes containing cancer-specific 
AS events, and found that most of them (68%–90%) do 
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not have significant change of expression levels between 
normal vs. tumor samples (Supplementary Figure S1A), 
suggesting that splicing of these events are not biased by 
their gene expression. In addition, we found that similar 
numbers of genes have increased vs. decreased PSI values, 
with exception of RI events that tend to have more retained 
introns (i.e. PSI increased) in cancers (Supplementary 
Figure S1B). Intron retention is a relatively less studied 
mode of AS in mammals and usually changes the coding 
frame and triggers nonsense mediated mRNA decay (NMD) 
[28]. Therefore an increase in intron retention may represent 
an important mechanism for protein inactivation in tumors.
Figure 1: Identification of AS events altered in cancers. (A) Analysis pipeline to identify AS events that are differentially spliced 
in cancer vs. normal tissues. (B) Venn diagram of differentially spliced AS events that are specific to one or multiple types of cancers in 
four different AS modes (SE, RI, A3SS and A5SS). (C) Numbers of AS events overlapped in the simulated dataset (white boxes) and the 
real dataset (gray boxes). We randomly selected the matched number of AS events from all the detectable AS events for each cancer and 
then calculated the overlaps. This procedure was repeated 1000 times, and the mean and range of numbers of overlapped events are shown.
Table 1: Summary of cancer dataset
Tumor Type No. of normal 
samples




No. of AS events 
detected
No. of AS events 
changed in cancer vs. 
normal
BRCA (breast cancer) 91 727 1.3E + 11 65,152 2,626
LIHC (liver cancer) 36 74 1.6E + 10 70,342 1,978
LUSC (lung cancer) 43 348 6.4E + 10 70,637 4,636
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Consistent change of cancer-specific AS events 
across tumor types
To determine if the cancer-specific AS events 
change consistently among different types of cancers, we 
compared the difference of PSI values between cancer and 
normal (ΔPSI) across three cancer types for each event 
(Figure 2A). The majority (i.e. 85%) of these cancer-
specific AS events change consistently across different 
tumor types (i.e., with an increased or decreased PSI values 
in all three tumors) when comparing tumors to the cognate 
normal tissue, suggesting that the splicing change in these 
Figure 2: Examples of cancer-specific AS events. (A) Changes of splicing across different cancer types. For all cancer-specific AS 
events, the differences of mean PSI values between cancer and normal samples were calculated. We plotted the percent of AS events with 
PSI changed in same direction among all cancers (purple) or in different directions for one specific type of cancer (BRCA, LUSC or LIHC). 
(B) Change of splicing in selected examples of cancer-specific AS events. The PSI values of paired samples are marked on the left (normal) 
and right (tumor) panel in each ladder plot with a colored line linking two PSI values. Blue lines represent AS events with increased PSIs 
in tumor, whereas red lines represent events with decreased PSIs and grey lines represent events with negligible change of PSI (< = 0.05). 
Box plots in the bottom are comparisons between all normal samples (white boxes) and all tumor samples (grey boxes). (C) PPI networks 
of genes containing cancer-specific AS events. The networks have 3 highly connected clusters defined by MCODE (color coded in pink, 
yellow and green). The hub proteins interacting with multiple clusters were coded with multiple colors. Three genes that are also frequently 
mutated in tumors were marked by red circles. The most enriched function/GO-term was labeled next to each cluster.
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genes will likely generate similar functional consequences 
across different tumors. The remaining 15% of AS events, 
while being altered across all cancers, have different 
patterns of splicing changes depending on the cancer type.
Representative examples of cancer-specific AS 
events were arbitrarily selected to illustrate splicing 
changes between tumor and normal samples. We chose 
one example from each AS mode and used colored lines 
to represent the ΔPSI between the paired tumor vs. the 
adjacent normal tissue (Figure 2B, upper panel). We 
found that there is large heterogeneity of ΔPSI between 
the paired cancer-normal samples. In some cases of breast 
cancer, both an increase and decrease in PSI were found 
among different patients, which might reflect differences 
between breast cancer subtypes. In addition, we also 
plotted the distribution of the PSI for the same examples in 
all normal and tumor samples, and found that the changes 
of PSI are consistent with those found in paired samples 
(white and gray boxes, bottom of Figure 2B).
Biological functions of cancer-specific AS events
We further examined the genes containing newly 
identified cancer-specific AS events, and found that 
many of these genes are known to play a key roles in 
different stages of tumor progression (Supplementary 
Table S1). Most of these genes are functionally related 
to each other and form closely connected protein 
interaction networks (Figure 2C). Based on the MCODE 
clustering algorithm [29], these genes can be clustered 
into three groups connected by several hub proteins 
(Figure 2C and Supplementary Table S2). The largest 
group contains genes involved in cell cycle regulation 
(such as AURKB, CDCA5), with genes in the other two 
groups having functions in mediating cell adhesion/
migration (e.g. CD44 and Collagens) and involved in 
the insulin signaling pathway (e.g. INSR, PPARG). 
The functional clustering of genes with cancer-specific 
AS suggests that the regulation of AS in cancer plays 
important roles in key pathways related to cancer 
pathogenesis, including cell cycle and cell adhesion/
migration. The association of insulin response pathway 
with splicing regulation in cancer has not been reported 
before, and its functional implication will be an 
interesting subject of future studies.
To further study the functional consequence 
of cancer-specific AS events in an unbiased fashion, 
we performed gene ontology (GO) analysis on genes 
containing cancer-specific AS events using the DAVID 
online tool (http://david.abcc.ncifcrf.gov/) [30, 31]. 
We found that the most enriched functional categories 
included cell adhesion, cell division, cell cycle and so on. 
(Figure 3A). We also did GO analysis on each individual 
cancer type and ranked enriched GO terms by their p-value 
(Supplementary Figure S2A to S2C). The top enriched 
terms were cytoskeleton proteins and proteins associated 
with cell adhesion, ATP-binding, cell cycle.
Sequence characteristics of cancer-specific AS 
events
The skipped exon is the most common mode 
of AS among all identified cancer-specific AS events 
(Figure 1B), providing a sufficient amount of data for 
detailed sequence analyses. We first measured the length 
of all skipped exons, and found no obvious difference 
between the cancer-specific SEs, the SEs that are altered 
in a single cancer type, and all annotated SEs as control 
(Figure 3B). We further examined if the lengths of these 
alternative exons can be divided by three, which is a good 
indication of how each AS event affects mRNA reading 
frame. We found that 42% of the alternative exons in 
control set of SEs are phase 0 exon (i.e. maintain their 
reading frame), while in the sets of SEs altered in single 
or multiple types of cancers, a notably increased fraction 
of exons maintain their reading frame (Figure 3C). In 
particular, 53% of the SEs shared by all three cancers are 
phase 0 exons, significantly more than what is expected by 
chance (p = 0.008 by fisher’s exact test). Since disruption 
of reading frame often introduces premature stop codons 
that lead to NMD, the increased tendency of cancer-
specific SEs to maintain reading frame suggests that these 
events tend to produce proteins with different functions 
rather than disrupting protein function via changing 
reading frame.
Alternative splicing is generally regulated by cis-
acting SREs that function as splicing enhancers or silencers 
[12]. These SREs usually function in the nearby region of 
alternative splice sites, and thus the pre-mRNA regions 
within and adjacent to the alternative exons are more 
conserved than corresponding regions near the constitutive 
exons. When further examining the conservation of pre-
mRNA regions near 124 cancer-specific SEs shared by 
three cancer types, we found that these exons tend to be 
highly conserved across 100 vertebrate species in the 
adjacent regions. Such sequence conservation is even 
higher than alternative exons that are spliced in a cancer-
independent manner (Figure 3D, comparing black and 
grey lines), suggesting that cancer-specific alternative 
exons are under additional evolutionary constraints. This 
result is consistent with the notion that alternative splicing 
of cancer-associated genes are tightly controlled in normal 
cells across different species to mediate critical and highly 
conserved processes in cell growth.
To further identify putative SREs that control 
cancer-specific SEs, we examined these highly conserved 
regulatory regions to measure whether there are enriched 
sequence motifs that could be potentially recognized by 
splicing factors (Supplementary Figure S3). Some of these 
motifs resemble the binding site of known splicing factor. 
For example, the AC-rich motifs are recognized by hnRNP 
L and the UG rich motifs resemble hnRNP H/F binding 
sites [14]. Consistently, the hnRNP H was shown to be 
up-regulated in certain cancer and control several cancer 
related splicing events [32, 33].
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Splicing of cancer-specific AS events are highly 
fluctuated
The ratios between different splicing isoforms 
of the same gene are tightly regulated to ensure precise 
control of gene function. In normal cells, splicing is 
usually controlled in a tissue-specific fashion with 
certain dominant isoforms in different tissues [24, 25]. 
However, such dominance of certain tissue-specific 
isoforms is often absent in cancer cells. In another word, 
many splicing isoforms are found in the “wrong tissues”, 
leading to a more dispersed spectrum of AS. However 
such deregulation of AS in cancer has only been observed 
in an anecdotal fashion, and a thorough investigation with 
correct controls is lacking.
To examine potential splicing deregulation in 
cancers, we directly test: (i) if the splicing of cancer-
specific AS events have higher variability than control 
events, and (ii) if such variability is higher in cancer vs. 
normal samples. We calculated the standard deviation 
Figure 3: Molecular features of AS events changed in cancers. (A) The genes containing 163 cancer-specific AS events were 
analyzed by gene ontology, and the significantly enriched (p < 0.005) GO terms are plotted. (B) Box plots of the length of alterative exons 
in the SE events from the MISO database, the SE events that were changed in LIHC, LUSC, BRCA, and the SE events altered in all cancers 
(from the left to the right). (C) Percent of skipped exons in each exon phase. Exons are classified into phase 0, 1, and 2 depending on the 
reminders when dividing their length by 3. Phase 0 (white boxes): events without frame-shift; Phase1 and 2 (black and gray boxes): events 
with frame-shift. The order is same as (B). Asterisks indicate significant increase of phase 0 exon ( p < 0.05 by Fisher’s exact test). (D) 
Sequence conservation near the cancer-specific skipped exons and all skipped exons. Black line represents average conservation score from 
the 124 cancer-specific SE events; grey line represents average conservation score from all the SE events in MISO database (control). (E) 
We compared the distribution of PSI standard deviation between control AS (left) and AS events that change in each cancer (right). We also 
compared those between normal (white box) and tumor samples (grey box).
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(SD) of PSI value for each AS event, which measures the 
amount of variation from the average. The SDs of cancer-
specific AS events were compared to those of control AS 
events across both normal and tumor samples in each 
cancer type. Since the mean value of PSI dramatically 
affects its SD (Supplementary Figure S4, PSI values near 0 
or 1 tend to have smaller SD), we randomly picked control 
AS events from the MISO database with PSI distribution 
matched to cancer-specific AS events. The selection of 
such controls can eliminate potential biases caused by 
different PSI distribution between cancer-specific AS 
events vs. all other AS events.
We found that all the cancer-associated AS events 
have higher PSI variation than controls in all three tissue 
types (Figure 3E, comparing 2 boxes at the right to the 
ones at left), suggesting that splicing of these events 
are indeed highly variable across different samples. In 
addition, when comparing the cancer-specific AS event 
in tumor sample with normal samples, those cancer-AS 
events still tend to have higher variability in tumors than in 
normal samples (p-value: 1.2 × 10−17, 5.3 × 10−6 and 6.0 × 
10−6 for BRCA, LIHC and LUSC respectively, Figure 3E). 
In each cancer type, we also plotted the distribution of PSI 
in histograms in supplementary figure S5 using both all 
AS events and the 163 cancer-specific events. This result 
is consistent with the popular hypothesis that the tissue 
specificity of AS in normal samples is disrupted in cancers, 
probably due to extensive changes in the expression levels 
and/or activities of oncogenic splicing factors.
Cancer-specific AS events as molecular 
biomarkers
Identification of a core set of cancer-specific AS 
events makes it possible to use this relatively small dataset 
as a new molecular biomarker of cancers. To this end, we 
conducted principal component analysis (PCA) using the 
163 cancer-specific AS events. For each tumor or normal 
sample, we generated a vector with 163 variables using the 
PSI values of cancer-specific AS events. We constructed 
a data matrix consist of all tumor and normal samples in 
each cancer type and further analyzed with PCA. The first 
two principal components in PCA accounted for 30%, 
25% and 24% of the total variance for LIHC, LUSC and 
BRCA samples respectively (Supplementary Figure S6). 
The distribution of all samples was plotted using the first 
two principal components, which show a clear separation 
between cancer and normal samples (Figure 4A). All 
analyses showed a reliable separation of samples into two 
clusters (labeled with red and blue for tumor and normal 
samples respectively), suggesting that the 163 cancer-
specific AS can potentially serve as a reliable biomarker 
for cancer diagnosis.
In addition, we combined all samples from three 
types of cancers and analyzed combined data with a 
similar PCA procedure. Consistent with our analyses of 
single cancer type, the cancer and normal samples can be 
reliably separated with the first two principal components 
(Figure 4B, “C” for cancer and “N” for normal), indicating 
that cancer-specific AS events are useful molecular 
biomarkers to separate tumors from mixed samples. In 
addition, the samples from different tissue types can be 
roughly separated (Figure 4B, with orange, green and 
black representing breast, lung and liver respectively). 
This result suggests that although the 163 AS events 
are identified based on their altered splicing in multiple 
cancers, their splicing patterns still partially reflect tissue 
of origin.
Breast cancer is a well-annotated cancer type in 
TCGA data and is classified into several subtypes based 
on histopathological criteria and expression of a core 
set of genes [34, 35]. The breast cancer cells in different 
subtypes (Claudin-low, Basal-like, HER2-enriched, 
Luminial B and Luminal A) resemble cells in different 
stages of normal mammary development, which is well 
correlated with tumor progression (Figure 5A) [35]. Since 
our BRCA dataset has a large number of samples with 
well-annotated subtype categories, we sought to determine 
if the cancer-specific AS events can be used to separate 
cancer subtypes. We conducted a similar PCA procedure 
using 818 breast samples that were independently 
classified into normal and four cancer subtypes by PAM50 
[34]. By plotting all samples along the first two principal 
components, we found that different breast cancer 
subtypes tend to be clustered into different groups (Figure 
5B). Certain subtypes of breast cancers, such as basal and 
luminal types, are particularly well separated. In addition, 
some normal samples that were misclassified as luminal 
A cancers by PAM50 were correctly distinguished using 
cancer-specific AS events, suggesting that the cancer-
specific AS events can potentially serve as a cancer 
biomarker independent of current classification criteria 
using gene expression data. Although current separation 
by two PCA components is not very strong with some 
overlaps between subtypes, this analysis provided a proof-
of-concept for splicing-based tumor classification. A more 
sophisticated statistical approach and analysis is needed 
to prove this. A representative example of cancer-specific 
AS events was selected to show that alteration of splicing 
patterns in the same gene could be different in distinct 
subtypes of breast cancer (Figure 5C), with the luminal 
A subtype having the largest variability between patients.
Ratio of different splicing variants can serve as 
predictor of cancer survival
Until around 2000, the chance of survival for 
cancer patients was mainly predicted according to various 
histologic and clinical characteristics. The advance of 
microarray technology led to more accurate profiling of 
gene expression in cancers, allowing prediction of cancer 
survival by the gene-expression signature of cancer [36, 37].
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The extensive splicing mis-regulation and frequent 
mutations of certain splicing factors in cancer have 
suggested that some AS events may directly affect tumor 
biogenesis and progression, however the consequence 
of splicing mis-regulation on patient survival remains 
unclear. The identification of cancer-specific AS events 
across a large number of patients makes it possible to test 
if splicing misregulation in certain genes can serve as a 
predictor of cancer prognosis.
We directly test this possibility using TCGA dataset 
of breast cancer which has largest number of patients. We 
separated 727 BRCA patients according to the ratio of 
Figure 4: PCA analysis using cancer-specific AS events. (A) PCA analysis of the 110 liver tissue samples (LIHC: 36 normal and 
74 tumor), 391 lung tissue samples (LUSC: 43 normal and 348 tumor) and 818 breast tissue (BRCA: 91 normal and 727 tumor) using the 
163 cancer-specific AS events. Tumor samples are in red circles and normal samples are in blue circles. (B) PCA analysis of samples from 
all three tissues using the 163 cancer-specific AS events. Samples were color-coded as its origin tissue. The cancer samples are labeled as 
“C” and the normal samples are labeled as “N”.
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Figure 5: Using cancer-specific AS events to separate breast cancer subtypes. (A) An overview of four different breast cancer 
subtypes in tumor developments. (B) PCA analysis of the 818 breast tissue using the 163 cancer-specific AS events. Different BRCA 
samples were labeled according to each subtype as classified by PAM50. (C) An example SE event where the different BRCA subtypes 
have different splicing patterns. The ladder plots were generated as described in figure 2B. (D) Two examples of cancer-specific AS events 
whose PSI value can be used to predict survival of breast cancer patients.
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different splicing isoform for each cancer-specific AS event 
(i.e. patients with high vs. low PSI values), and examine if 
such classification is correlated with the overall survival 
of BRCA patients using Kaplan-Meier analysis. We found 
that five of cancer-specific AS events indeed can be used 
as predictor of tumor survival (log rank p < 0.05), with two 
examples shown in figure 5D. The first example, WBP1 
(WW domain binding protein 1), is a binding partner of 
WWOX tumor suppressor that is frequently mutated in 
breast cancer [38]. We found that increased retention 
of intron 3 in WBP1 is associated with poor prognosis 
(Figure 5D). The second example, GPR116, is an adhesion 
G-protein-coupled receptor that promotes breast cancer 
metastasis [39]. The inclusion of an alternative exon at end 
of GPR116 will generate a non-canonical isoform (isoform 
2) with a different C-terminal cytoplasmic domain that may 
change its ability to interact with downstream signaling. 
We found that the increased production of isoform 2 is 
associated with poor prognosis. Taken together, our data 
show that, for the first time, the splicing ratio of some 
human genes in cancers is associated with cancer survival, 
suggesting the possibility to use gene splicing as a new 
molecular signature to predict cancer prognosis.
Possible regulators of cancer-specific AS
AS is generally controlled by various trans-acting 
splicing factors that specifically recognize cis-acting SREs 
in pre-mRNA. The level and activity of splicing factors 
usually vary in different cells, leading to the distinct AS 
patterns in corresponding cell types. Since splicing factors 
are often controlled by their coexpressed and functionally 
interacted proteins in different cellular signaling 
pathways [4], the splicing profile in certain cells may be 
significantly correlated with the expression of genes that 
play regulatory roles in AS. Therefore, given a large set of 
mRNA-seq data across different samples, a global analysis 
of correlations between AS patterns and expression of all 
genes may reveal regulatory relationships.
To explore possible regulatory mechanisms of 
cancer-specific AS, we systematically calculated the 
correlation between the PSI value of the 163 cancer-
specific AS events and the expression of all detectable 
genes (Figure 6A). We found that the set of cancer-
specific AS events are indeed significantly correlated with 
expression of many genes, among which are 304 genes 
highly correlated with more than 30 cancer-specific AS 
events. This set of genes are either positively or negatively 
correlated with the PSI values of many cancer-specific AS 
events, and thus may reflect potential regulatory pathways 
for the associated AS events.
We further conducted GO analysis on genes 
significantly associated with cancer-specific AS events, 
and found that the vast majority of them function in 
multiple pathways related to cell cycle regulation 
(Figure 6B). However, the functional category of 
RNA-binding is not significantly enriched in the set 
of genes associated with cancer-specific AS. We were 
a little surprised by the small number of correlated 
splicing factors. However, splicing factor activities can 
also be regulated in the level of protein modification, 
and indeed we found that the phosphorylation of several 
splicing factors is cell cycle dependent (Dominguez at al, 
unpublished data). This result suggests that the activity 
of splicing factors may be controlled in a cell cycle 
dependent manner (e.g., through protein phosphorylation), 
and thus cell cycle proteins can indirectly affect splicing 
in tumor cells.
In addition, we analyzed protein-protein interaction 
among the genes correlated with cancer-specific AS 
using the STRING database. We found that 173 out of 
the 304 genes are highly connected with each other, and 
surprisingly the two largest clusters in the interaction 
network consist predominantly of genes that mediate 
the two major cell cycle checkpoints (i.e. checkpoint for 
G1-S and G2-M transition, Figure 6C). The genes in the 
largest cluster remarkably form a complete graph with 32 
nodes, of which each connects with all others to function 
in kinetochore formation, cell division and mitosis (red 
cluster in Figure 6C, also see Supplementary Table S3). 
The second biggest group has 18 genes that are mostly 
involved in DNA replication. Even the smaller clusters 
have cell cycle related functions such as P53 signaling, M 
phase, DNA repair, and condensin complex. Such a high 
degree of correlation between cell cycle regulation and 
cancer-specific splicing has not been previously reported 
but has profound implication in how AS is controlled in 
multiple cancers.
DISCUSSION
Here we performed a systematic identification and 
analysis of cancer-specific AS events using thousands 
of patient samples from TCGA data. To increase the 
statistical power of our analyses, we selected three types 
of cancers that have a relatively large number of paired 
normal controls. These tissue types are sufficiently 
different to enable us to filter out tissue-specific splicing, 
as most identified AS events are altered in only a single 
type of cancer (Figure 1B). The AS events significantly 
altered in all three cancer types include many genes 
whose splicing was known to play critical roles in cancer 
development, such as the CD44 [8], NUMB [40, 41], and 
FN1 [42]. These genes probably represent a core set of 
cancer-specific AS events that affect key pathways in 
cancer progression.
On the other hand, several AS events that have well-
known roles in cancer development were not identified by 
our procedure, probably due to the high stringency used 
in our filters. For example, our set of cancer-specific AS 
does not include Bcl-x, whose splicing is known to control 
cell apoptosis in multiple tumors [9] and can be used as 
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a potential therapeutic target [43, 44]. However the ΔPSI 
of Bcl-x is not large enough to pass the thresholds in our 
pipeline, and we expect that additional cancer-specific 
AS events can be identified when the criteria are relaxed. 
We also require the AS events to be detected in ~30% of 
normal liver samples (10 out of 36, see table 1), which may 
cause some uncommon events to be omitted in our pipeline.
Although most cancer-specific AS events are 
involved in cellular pathways critical to cell growth and 
migration, they may not directly drive the initial stages of 
tumorigenesis, as we could not detect obvious mutations 
near the splice sites of these alternatively spliced exons. 
Instead we speculate that they are more likely to be a result 
of mis-regulated splicing factors that potentially change 
splicing of many pre-mRNA targets. Consistently, several 
splicing factors were found to be mutated or significantly 
changed in expression between cancers and normal tissue, 
including SRSF1, QK1, RBM4, RBM5/6/10, and hnRNP A2 
[19, 20, 40, 41, 45]. These results imply that cancer-specific 
AS events will be more useful as cancer biomarkers, whereas 
the splicing factors may better serve as potential therapeutic 
targets to restore mis-regulated splicing in cancer.
Figure 6: Genes associated with cancer-specific AS events. (A) Flow chart of identifying possible regulators of cancer-specific 
AS. (B) Gene ontology analysis of the 304 genes that are highly correlated with the 163 tumor AS events. (Spearman rank correlation > = 
0.4 across 1319 samples, p-value < 0.005, and correlated with more than 30 out of the 163 tumor AS). (C) PPI networks of genes that are 
highly correlated with the 163 cancer-specific AS events. Color-coded proteins are clustered by MCODE. Light purple-colored nodes were 
proteins that were not clustered into any group by MCODE. The most enriched function/GO-term was labeled next to each cluster. The 
genes involved in RNA binding and splicing regulation are also indicated at the bottom.
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To study potential regulatory mechanisms for the 
cancer-specific AS events, we used an association study to 
identify genes whose expression is correlated with these 
events across thousands of tumor and normal samples. 
This large dataset size enables a statistically reliable 
identification of genes that directly or indirectly regulate AS. 
Such analyses only identified a small number of putative 
splicing factors including hnRNP L and snRPA1 (Figure 
6C, marked at the bottom). We speculate that this is due to 
the large heterogeneity among tumor samples, as the known 
cancer-related splicing factors are found to be altered in 
only a subset of tumor samples. Remarkably, the majority of 
genes whose expression is associated with cancer-specific 
AS events are those involved in cell cycle regulation, 
revealing an unknown link between cell cycle and splicing 
regulation. An unbiased clustering of these associated 
genes recapitulated two major cell cycle checkpoints (i.e., 
G1 to S and G2 to M transition) and several main control 
pathways for cell cycle progression (e.g., DNA repair and 
P53 signaling). Although the reason of such high correlation 
is not clear, there are several interesting implications and 
predictions. For example, this result may suggest that 
genes controlling cell cycle progression also play a central 
regulatory role in pre-mRNA splicing and processing. Since 
cancer cells undergo fast growth and division compared to 
normal cells, there may be an increasing pressure for cancer 
cells to transcribe and splice certain genes at a high rate in 
some cell cycle stages. Because most introns are spliced 
co-transcriptionally, the increased transcription rate may 
directly affect AS of a certain set of genes in cancer. There 
may also be epigenetic factors that bridge the regulation of 
cell cycle with alternative splicing. A careful examination 
of this link requires integration of the changes in various 
epigenetic markers and transcription factors with splicing 
alteration, which will be an important direction for future 
investigation. Another interesting implication is that 
AS may be temporally regulated during the cell cycle. 
Although periodic gene transcription during cell cycle is 
well documented [46], there are limited reports on temporal 
regulation of splicing at different cell cycle stages. Our 
result implies that such a regulation mode is likely to 
exist and may even be a major mechanism responsible for 
cancer-specific AS.
In summary, this study generated a common set of 
cancer-specific AS events across different cancer types, 
which can be used as novel cancer biomarkers. We 
provided a detailed picture of unique features for these AS 
events and mechanistic insights on how splicing is mis-
regulated in cancer. Because dysregulation of splicing in 
cancer can often serve as a cancer progression indicator, 
the identification of a core set of cancer-specific AS events 
will likely help early cancer detection and thus improve 
the chance of cure. Finally, this relative small set of AS 
events will facilitate direct discovery of key regulators that 
are responsible for splicing dysregulation in cancers and 
thus can potentially be used as new therapeutic targets.
MATERIALS AND METHODS
Data acquisition and sequence processing
Pair-ended RNA-seq data were acquired from the 
TCGA consortium, with each sample having an average of 
> 150 million reads. The reads were aligned to the human 
genome version hg19 with MapSplice V2.0 [47], and the 
gene expression values were estimated using the RSEM 
pipeline [48] and normalized to the upper quartile of all 
expressed genes [49].
To analyze AS events on a genomic scale, we used 
the MISO [50] event-centric pipeline with the hg19 v2.0 
annotation to calculate the inclusion ratio of all annotated 
AS isoforms. To qualify as a valid AS events, we require 
that both isoforms are detectable in at least 10 normal 
samples and 10 tumor samples for each cancer type. See 
Supplementary Methods for details.
Determination of AS events shared between 
cancer types
To examine the statistical significance for the 
number of AS events that are in common between 
different cancers, 1000 simulated datasets were generated 
by randomly selecting a control set of AS events with 
matched size in each cancer type (number of AS events 
for lung, liver and breast cancer respectively: SE: 3111, 
1308, 1804; RI: 378, 109, 201; A3SS: 614, 317, 331; 
A5SS: 533, 244, 290). We then computed the number of 
events that were common across multiple cancer types. In 
each AS mode (SE, RI, A3SS and A5SS), we generated 
1000 simulated datasets and calculate the mean overlaps 
between different cancers, which were then compared to 
the overlaps of real data using rank test.
Motif enrichment analysis
The enriched RNA motifs near the splice sites of 
cancer-specific AS events were calculated by counting all 
5-nt “words” near the alternative exons and computing 
the Z-score as described earlier [51]. All 5-mers with 
Z-score larger than 2.5 were then clustered by sequence 
similarity and multiply aligned by using CLUSTALW to 
identify candidate motifs. See Supplementary Methods 
for details.
Principal component analysis (PCA)
PSI values of the 163 cancer-specific AS events 
were used to form the data vector for PCA. For each 
cancer type, the PSI vectors across all normal and tumor 
samples were then combined and used as the input data 
matrix to perform PCA. The distribution of normal and 
cancer samples across the first two components were 
plotted. See Supplementary Methods for details.
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Correlation between gene expression and AS
Correlations between genes and AS events were 
calculated using two matrices. The first matrix consists 
of the PSI values of 163 cancer-specific AS events across 
1319 cancer and normal samples. Another matrix contains 
the expression level of every gene across 1319 samples. 
We computed the spearman rank correlation, ρ (rho), 
between every two vectors from the two matrices. Each 
pair with |ρ| > = 0.4 and p < = 0.005 was considered as 
a highly correlated event-gene pair. See Supplementary 
Methods for details.
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